Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex versus bevacizumab during cataract surgery for diabetic macular edema or diabetic retinopathy
ACTRN12615000118505Phase 3Recruiting
- Sponsor
- Alice Springs Hospital
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of ozurdex and bevacizumab in diabetic macular edema (DME) and diabetic retinopathy (DR) (2 arms), sponsored by Alice Springs Hospital. Primary endpoint: Best corrected visual acuity. Started Aug 2015; status: recruiting.
02
Drugs
ozurdexbevacizumab
03
Conditions
diabetic macular edema (DME)diabetic retinopathy (DR)
Beyond the preview
Go deeper on ACTRN12615000118505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000118505.